56.28 USD
▼-1.91-3.28%
盘后 57.26 +1.74%
2026-09-15
市值
$5.45B
市盈率
—
EPS
-4.73
股息率
—
52 周区间
35.60 – 72.66
成交量
587.02K
Beta
0.62
目标价
81.21
52W 低 35.6052W 高 72.66
价格走势
公司简介
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In a...
关联新闻
- Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.'